Fluoroquinolones and anaerobesSTEIN, Gary E; GOLDSTEIN, Ellie J. C.Clinical infectious diseases. 2006, Vol 42, Num 11, pp 1598-1607, issn 1058-4838, 10 p.Article

Les effets indésirables des fluoroquinolones : Ils sont aussi psychiatriques !CHAGNON, André.Concours médical (Paris). 2006, Vol 128, Num 33-34, pp 1391-1392, issn 0010-5309, 2 p.Article

Classification of fluoroquinolonesNABER, K. G; ADAM, D.International journal of antimicrobial agents. 1998, Vol 10, Num 4, pp 255-257, issn 0924-8579Article

Les fluoroquinolones = FluoroquinolonesDAMAS, P.RMLG. Revue médicale de Liège. 1996, Vol 51, Num 1, pp 50-52, issn 0370-629XArticle

Optimizing fluoroquinolone utilization in a public hospital: a prospective study of educational interventionLACOMBE, K; CARIOU, S; TILLEUL, P et al.European journal of clinical microbiology & infectious diseases (Print). 2005, Vol 24, Num 1, pp 6-11, issn 0934-9723, 6 p.Article

The role of clonality in the global spread of fluoroquinolone-resistant bacteriaKLUGMAN, Keith P.Clinical infectious diseases. 2003, Vol 36, Num 6, pp 783-785, issn 1058-4838, 3 p.Article

Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection modelsPATEL, Mahesh V; DE SOUZA, Noel J; GUPTE, Shrikant V et al.Antimicrobial agents and chemotherapy. 2004, Vol 48, Num 12, pp 4754-4761, issn 0066-4804, 8 p.Article

Fluoroquinolone-associated tendinopathy: A critical review of the literatureKHALIQ, Yasmin; ZHANEL, George G.Clinical infectious diseases. 2003, Vol 36, Num 11, pp 1404-1410, issn 1058-4838, 7 p.Article

Symposium on new quinolonesDrugs (Basel). 1993, Vol 45, issn 0012-6667, 495 p., SUP3Conference Proceedings

Pharmacodynamic modeling of Carbapenems and fluoroquinolones against Bacteria that produce extended-spectrum beta-lactamasesMOCZYGEMBA, Leticia R; FREI, Christopher R; BURGESS, David S et al.Clinical therapeutics. 2004, Vol 26, Num 11, pp 1800-1807, issn 0149-2918, 8 p.Article

Innovations pharmacologiques, le modèle des fluoroquinolones = Pharmacological innovations, the fluoroquinolone modelBERGOGNE-BEREZIN, E.La Presse médicale (1983). 2003, Vol 32, Num 10, pp 466-469, issn 0755-4982, 4 p.Article

Fleroxacin clinical pharmacokineticsSTUCK, A. E; KIM, D. K; FREY, F. J et al.Clinical pharmacokinetics. 1992, Vol 22, Num 2, pp 116-131, issn 0312-5963Article

Quinolone mode of action : new aspectsHOOPER, D. C.Drugs (Basel). 1993, Vol 45, pp 8-14, issn 0012-6667, SUP3Conference Paper

Transinstestinal elimination of ciprofloxacin in humans. Concomitant assessment of its metabolites in serum, ileum, and colonVIELL, B; KRAUSE, B; VESTWEBER, K.-H et al.Infection. 1992, Vol 20, Num 6, pp 324-327, issn 0300-8126Article

Synthesis of [carbonyl-¹⁴C]sparfloxacinKAGEMOTO, A; NEGORO, T; NAKAO, M et al.Arzneimittel-Forschung. 1991, Vol 41, Num 7, pp 744-746, issn 0004-4172Article

Fluoroquinolone antibiotics in the environmentSUKUL, Premasis; SPITELLER, Michael.Reviews of environmental contamination and toxicology. 2007, Vol 191, pp 131-162, issn 0179-5953, 32 p.Article

Antibacterial activity and mechanism of action of a novel anilinouracil -fluoroquinolone hybrid compoundBUTLER, Michelle M; LAMARR, William A; BOWLIN, Terry L et al.Antimicrobial agents and chemotherapy. 2007, Vol 51, Num 1, pp 119-127, issn 0066-4804, 9 p.Article

Ciprofloxacin-induced anaphylactoid reactionKOTHUR, Kavitha; SINGH, Meenu; DAYAL, Devi et al.European journal of pediatrics. 2006, Vol 165, Num 8, pp 573-574, issn 0340-6199, 2 p.Article

Dual targeting of topoisomerase IV and gyrase to reduce mutant selection : Direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacinSTRAHILEVITZ, Jacob; HOOPER, David C.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 5, pp 1949-1956, issn 0066-4804, 8 p.Article

The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomyBURKA, Jenna M; BOWER, Kraig S; VANROEKEL, R. Cameron et al.American journal of ophthalmology. 2005, Vol 140, Num 1, pp 83-87, issn 0002-9394, 5 p.Article

New milestones achieved in fluoroquinolone safetyTILLOTSON, Glenn S; RYBAK, Michael J.Pharmacotherapy. 2001, Vol 21, Num 3, pp 358-360, issn 0277-0008Conference Paper

Fluoroquinolone resistance in staphylococci : new challengesSANDERS, C. C; SANDERS, W. E; THOMSON, K. S et al.European journal of clinical microbiology & infectious diseases (Print). 1995, Vol 14, pp S6-S11, issn 0934-9723, SUP1Conference Paper

Effect of the new quinolone antibacterial agent levofloxacin on multiple organ carcinogenesis initiated with wide-spectrum carcinogens in ratsKAJIMURA, T; TOJO, H; KUDO, G et al.Arzneimittel-Forschung. 1992, Vol 42, Num 3A, pp 390-395, issn 0004-4172Article

Pharmacokinetics of temafloxacin in humans after multiple oral dosesGRANNEMAN, G. R; CARPENTIER, P; MORRISON, P. J et al.Antimicrobial agents and chemotherapy. 1992, Vol 36, Num 2, pp 378-386, issn 0066-4804Article

In vitro evaluation of BAY Y3118, a new full-spectrum fluoroquinoloneBREMM, K. D; PETERSEN, U; METZGER, K. G et al.Chemotherapy (Basel). 1992, Vol 38, Num 6, pp 376-387, issn 0009-3157Article